Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non–small-cell Lung Cancer

This publication has 30 references indexed in Scilit:

• HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
  Cancer Discovery, 2012
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
  The Lancet Oncology, 2012
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
  The Lancet Oncology, 2011
• Cyclin D as a therapeutic target in cancer
  Nature Reviews Cancer, 2011
• Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
  New England Journal of Medicine, 2010
• Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
  New England Journal of Medicine, 2009
• Measures to assess the prognostic ability of the stratified Cox proportional hazards model
  Statistics in Medicine, 2009
• Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
  British Journal of Cancer, 2008
• The Phosphoinositide 3-Kinase Pathway
  Science, 2002
• Key Concepts in Model Selection: Performance and Generalizability
  Journal of Mathematical Psychology, 2000